The MICROB-PREDICT project investigates the human microbiome to identify predictors and mechanisms associated with the development of decompensation of cirrhosis and progression to acute-on-chronic liver failure (ACLF) and death. The project will last six and a half years, starting from 1st of January 2019. Project unites the expertise from 22 different European partners (hospitals, research foundations and institutes, patient and physician associations, and small-and-medium-sized enterprises, SMEs) and has received funding of 15 million EUR from the European Union’s Horizon 2020 research and innovation programme under grant agreement No. 825694.
Liver cirrhosis represents the end-stage of a chronic disorder which results in severe and permanent damage of a vital organ. In recent years, liver cirrhosis was one of the leading causes of death in adults worldwide, both in males and females. The number of deaths due to cirrhosis in Europe has been estimated to be around 170,000 annually, with varying mortality rates in different European countries.
ELPA is proud to support and collaborate with partners within GALAXY’s project Advisory Board (gut-and-liver axis in alcoholic liver fibrosis), the project that will investigate the precursor of alcoholic liver cirrhosis, i.e. alcoholic liver fibrosis to enable early detection and treatment. This will ultimately result in a reduction of mortality, morbidity, healthcare costs and lost productivity.